{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:05:09Z","timestamp":1766966709043,"version":"3.48.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Egypt Natl Canc Inst"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Multiple myeloma (MM) remains an incurable plasma cell malignancy despite advances with proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies. Bispecific antibodies (BsAbs) have emerged as a transformative, off-the-shelf immunotherapeutic strategy that redirects immune effector cells to eliminate malignant plasma cells. The recent FDA approvals of teclistamab, talquetamab, elranatamab and linvoseltamab have reshaped the therapeutic landscape of relapsed\/refractory MM (RRMM), achieving overall response rates (ORR) exceeding 60% in heavily pretreated patients. Teclistamab, targeting BCMA, demonstrated an ORR of 63%, while talquetamab, targeting GPRC5D, achieved an ORR of 74%, even in patients previously treated with T-cell redirection therapies. Elranatamab and linvoseltamab further enriched this armamentarium with comparable efficacy and favorable safety profiles. In addition to these milestones, early-phase data from emerging trispecific antibodies, such as ISB 2001, show ORRs as high as 75% and deep responses, including stringent complete responses (sCR) and minimal residual disease (MRD) negativity. This review provides an integrated analysis of BsAbs in MM, encompassing mechanisms of action, clinical development, efficacy, safety profiles, and future directions. We synthesize the latest clinical trial data, explore strategies for overcoming resistance, and discuss ongoing efforts to optimize combination regimens and sequencing. By critically evaluating these advancements, we highlight the evolving role of BsAbs and trispecific antibodies in redefining treatment paradigms, with the ultimate goal of improving patient outcomes and advancing toward a potential cure for multiple myeloma.<\/jats:p>","DOI":"10.1186\/s43046-025-00336-5","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:02:45Z","timestamp":1766966565000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current landscape and future prospects of bispecific antibodies in multiple myeloma"],"prefix":"10.1186","volume":"37","author":[{"given":"Sheilabi","family":"Seeburun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"336_CR1","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","volume":"398","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Garfall AL, van de Donk NWCJ, et al. Teclistamab, a B-cell maturation antigen\u2008\u00d7\u2008CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021;398:665.","journal-title":"Lancet"},{"key":"336_CR2","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29:2259.","journal-title":"Nat Med"},{"key":"336_CR3","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1200\/JCO.24.01008","volume":"42","author":"Naresh Bumma","year":"2024","unstructured":"Bumma Naresh, et al. Linvoseltamab for treatment of relapsed\/refractory multiple myeloma. J Clin Oncol. 2024;42:2702\u201312. https:\/\/doi.org\/10.1200\/JCO.24.01008.","journal-title":"J Clin Oncol"},{"issue":"31","key":"336_CR4","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1200\/JCO.22.01504","volume":"1","author":"A D'Souza","year":"2022","unstructured":"D\u2019Souza A, Shah N, Rodriguez C, Voorhees PM, Weisel K, Bueno OF, et al. A phase I first-in-human study of ABBV-383, a B-cell maturation antigen \u00d7 CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2022;1(31):3576\u201386. https:\/\/doi.org\/10.1200\/JCO.22.01504.","journal-title":"J Clin Oncol"},{"key":"336_CR5","doi-asserted-by":"publisher","unstructured":"Noffar Bar,\u00a0Maria Victoria Mateos,\u00a0Paz Ribas,\u00a0Markus Hansson,\u00a0Laura Paris,\u00a0Craig C. Hofmeister,\u00a0Paula Rodriguez Otero,\u00a0Maria Aranzazu Berm\u00fadez,\u00a0Thomas Martin,\u00a0Armando Santoro,\u00a0Andrew J. Yee,\u00a0Maria Creignou,\u00a0Cristina Encinas Rodriguez,\u00a0Claudio Cerchione,\u00a0Javier De La Rubia,\u00a0Albert Oriol,\u00a0Heidi Waibel,\u00a0Britta Besemer,\u00a0Ethan Thompson,\u00a0Brian Kiesel,\u00a0Jinjie Chen,\u00a0Alexander Chung,\u00a0Isaac W. Boss,\u00a0Allison Gaudy,\u00a0Shaoyi Li,\u00a0Kevin Hsu,\u00a0Colin Godwin,\u00a0Michael R. Burgess,\u00a0Jes\u00fas San-Miguel,\u00a0Luciano Costa; Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) \u00d7 CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed\/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study.\u00a0Blood\u00a02023; 142 (Supplement 1): 2011. https:\/\/doi.org\/10.1182\/blood-2023-180013","DOI":"10.1182\/blood-2023-180013"},{"key":"336_CR6","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495.","journal-title":"N Engl J Med"},{"key":"336_CR7","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood.2023023616","volume":"144","author":"C Touzeau","year":"2024","unstructured":"Touzeau C, Krishnan AY, Moreau P, et al. Efficacy and safety of teclistamab in patients with relapsed\/refractory multiple myeloma after BCMA-targeting therapies. Blood. 2024;144:2375.","journal-title":"Blood"},{"key":"336_CR8","doi-asserted-by":"publisher","first-page":"8036","DOI":"10.1200\/JCO.2023.41.16_suppl.8036","volume":"41","author":"Carolina D Schinke","year":"2023","unstructured":"Schinke Carolina D, et al. Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41:8036\u20138036. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.8036.","journal-title":"J Clin Oncol"},{"key":"336_CR9","unstructured":"Harrison SJ, Mateos MV, Cohen AD, et al. Forimtamig (RG6234): updated results from a phase 1 study in relapsed\/refractory multiple myeloma. ASH Annual Meeting. 2023. Abstract #248."},{"key":"336_CR10","doi-asserted-by":"crossref","unstructured":"Shaji Kumar et al.CAMMA 2: A phase I\/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed\/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent..\u00a0JCO\u00a041,\u00a0TPS8064-TPS8064 (2023).","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8064"},{"key":"336_CR11","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","volume":"24","author":"H Ludwig","year":"2023","unstructured":"Ludwig H, Terpos E, van de Donk N, et al. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol. 2023;24:e255.","journal-title":"Lancet Oncol"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-025-00336-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43046-025-00336-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43046-025-00336-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:02:48Z","timestamp":1766966568000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43046-025-00336-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["336"],"URL":"https:\/\/doi.org\/10.1186\/s43046-025-00336-5","relation":{},"ISSN":["2589-0409"],"issn-type":[{"value":"2589-0409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"15 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript is a narrative review of previously published studies and does not involve any new studies with human participants or animals conducted by the author.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"80"}}